Cencora Lifts View on Weight-Loss Drug Demand as Profit Surges

Dow Jones

May 07, 2025

By Rob Curran

Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%.

The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier.

Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share.

Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion.

Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources.

Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September to between $15.70 and $15.95 from a prior estimated range of $15.30 to $15.60.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

May 07, 2025 07:39 ET (11:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533989228"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533989228\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533989228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533989228","market":"hk","top_or_hot":-1,"title":"Cencora Lifts View on Weight-Loss Drug Demand as Profit Surges","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%. \n</p>\n<p>\n  The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share. \n</p>\n<p>\n  Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion. \n</p>\n<p>\n  Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources. \n</p>\n<p>\n  Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September to between $15.70 and $15.95 from a prior estimated range of $15.30 to $15.60. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cencora Lifts View on Weight-Loss Drug Demand as Profit Surges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCencora Lifts View on Weight-Loss Drug Demand as Profit Surges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 19:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%. \n</p>\n<p>\n  The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share. \n</p>\n<p>\n  Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion. \n</p>\n<p>\n  Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources. \n</p>\n<p>\n  Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September to between $15.70 and $15.95 from a prior estimated range of $15.30 to $15.60. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004303.SGD","symbol_name":"Nikko AM Shenton Global Opportunities SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533989228","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533989228","pubTimestamp":1746617940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%.The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier.Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share.Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion.Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources.Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4529":"IDC概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","COR":"CENCORA","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4175":"保健护理产品经销商","BK4585":"ETF&股票定投概念","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4084":"特种房地产投资信托"},"translate_title":"随着利润飙升，Cencora提升了对减肥药需求的看法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%. \n\n\n  The drug wholesaler formerly known as AmerisourceBergen logged earnings of $717.9 million, or $3.68 a share, for the fiscal second quarter ended in March, down from $420.8 million, or $2.09 a share, a year earlier. \n\n\n  Stripping out certain one-time items, Cencora's adjusted earnings were $4.42 a share, topping the average Wall Street target of $4.11 a share. \n\n\n  Revenue rose 10% to $75.45 billion, just shy of the mean analyst estimate of $75.68 billion. \n\n\n  Sales growth was particularly strong in its U.S. health-care unit, partly due to rising demand for glucagon-like peptide 1 inhibitors, the blockbuster class of drugs that includes Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Cencora also noted strong demand for specialty products from physicians' offices and other sources. \n\n\n  Cencora boosted its forecast for adjusted earnings per share for the fiscal year ending in September to between $15.70 and $15.95 from a prior estimated range of $15.30 to $15.60. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 07:39 ET (11:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}